Carlos L. Arteaga

Oncology · 2000–2022

A researcher in the Science corpus: 13 papers; trusts 7 researchers and is trusted by 8 researchers here, as inferred from the citation graph.

Subfields

Whom Carlos L. Arteaga trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. J. Engelman
  2. Y. Yarden
  3. J. Baselga
  4. William Pao
  5. H. Horlings
  6. C. Yun
  7. M. Sliwkowski
  8. R. Nahta
  9. R. Avraham
  10. L. Gianni

Who trusts Carlos L. Arteaga overall

  1. A. Hanker
  2. D. Sudhan

Papers from Carlos L. Arteaga's perspective

Ordered by how strongly the researchers Carlos L. Arteaga trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Untangling the ErbB signalling network (Nature reviews. Molecular cell biology)
  2. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets (Nature Medicine)
  3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
  4. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. (Cancer Cell)
  5. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy (Science)
  6. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. (Journal of Clinical Oncology)
  7. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. (Cancer Research)
  8. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. (New England Journal of Medicine)
  9. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. (Cancer Cell)
  10. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab (Nature)

Their papers